DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-04 ...

Group 1 - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment [1] - The article suggests that investors should consider buying NOK stock based on analysts' recommendations [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Bioventus is at a significant inflection point, focusing on four powerful growth drivers while aiming to enhance profitability, increase cash flow, and drive shareholder value [3]. Company Overview - Bioventus' mission is to assist patients in recovering and living life to the fullest [2]. - The company has undergone significant changes and demonstrated strong performance over the past few years [3]. Growth Strategy - The company is concentrating on igniting four key growth drivers to propel its future success [3]. - There is an emphasis on expanding profitability and increasing cash flow alongside growth initiatives [3].

Bioventus Conference Call Summary Company Overview - **Company**: Bioventus - **Industry**: Healthcare, specifically in pain treatments, surgical solutions, and restorative therapies - **Annual Revenue**: Over $550 million - **Market Opportunity**: Over $6 billion across its portfolio [3][4] Core Business and Growth Drivers - **Core Business**: Comprises HA, bone graft substitutes, and fracture care, generating significant cash flow and high margins [6] - **Expansion Platform**: Includes ultrasonics and international markets, expected to contribute significantly to revenue growth [6][12] - **Emerging Growth Platform**: Focuses on peripheral nerve stimulation (PNS) and platelet-rich plasma (PRP), with PNS projected to grow at around 24% and PRP over 10% [7][9] - **Revenue Contribution**: By 2026, PNS and PRP are expected to contribute 200 basis points of growth [10] Financial Performance - **Gross Margin**: Peer-leading gross margin in the mid-70s% [15] - **EBITDA Margin**: Expanded by roughly 700 basis points [4] - **Operating Cash Flow**: Over $100 million generated in the last two years, with expectations for cash flow to double in 2025 [5][34] - **Debt Reduction**: Debt reduced to below $300 million, with a leverage ratio below 2.5 times [16] Strategic Initiatives - **Investment Focus**: Disproportionate investment in expansion and emerging platforms, including PNS sales organization and international sales resources [13][14] - **International Expansion**: Targeting EMEA and APAC regions with a disciplined approach to market entry [29][30] - **M&A Strategy**: High bar for M&A, focusing on synergistic opportunities that meet strong financial metrics [17][32] Market Position and Competition - **PNS Technology**: Unique advantages include being the only technology designed for peripheral nerves, with a full launch expected soon [8][22] - **Ultrasonics**: Aiming to establish this technology as the standard of care in spinal surgery through education and marketing [25][26] - **PRP Market**: Positioned to leverage existing HA salesforce, emphasizing customization and efficiency in treatment [9][27] Macroeconomic Considerations - **Tariff and FX Headwinds**: Anticipated $1-$2 million in tariffs for 2026, with a proactive management approach to overcome these challenges [35][36] Conclusion - **Future Outlook**: Bioventus is positioned for significant growth with a strong foundation, focusing on expanding its portfolio and enhancing profitability while managing financial discipline [18]

Core Viewpoint - Bioventus Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its innovations in active healing [1] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [2] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [2] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [2]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Bioventus Inc. which may affect shareholder rights [1] Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Bioventus may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced shareholder value [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Core Viewpoint - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues, particularly when ad-blockers are enabled [1] Group 1 - The article suggests that users may face restrictions if they have ad-blockers enabled, indicating a need for adjustments in browser settings to ensure smooth access [1]

Summary of Bioventus Conference Call Company Overview - **Company**: Bioventus - **Industry**: Medical Technology (Med Tech) - **Annual Revenue**: Over $550 million - **Market Opportunity**: $6 billion across product categories [4][5] Core Business Segments - **Business Segments**: - Pain Treatment - Surgical Solutions - Restorative Therapies - **Market Position**: Category or growth leader in all segments [4] Financial Performance - **Growth Rate**: Expected to grow nearly 2X the weighted average market growth rate despite unfavorable comparisons in the first half of the year [5] - **EBITDA Margin**: Guidance for the year is just over 20%, representing a 100 basis points improvement from the previous year [6] - **Cash Flow Improvement**: Significant progress with cash flow expected to nearly double this year, driven by higher EBITDA, lower interest expenses, and efficient working capital [17][18] Growth Drivers Core Growth Drivers - **Hyaluronic Acid (HA) Therapy**: - Focused on knee osteoarthritis pain with Durolane as a leading product - Strong clinical differentiation and largest dedicated sales force in the space [7][8] - **Bone Graft Substitutes (BGS)**: - Focused on spinal surgery with high single-digit growth [8] - **Fracture Care**: - Restored to growth with double-digit growth in recent quarters, expecting mid-single-digit growth moving forward [9] Expansion Growth Drivers - **Ultrasonics Technology**: - Aimed at changing the standard of care for bone cutting in spine surgery, expected to drive significant growth [10][11] - **International Segment**: - New leadership and plans to aggressively pursue international opportunities, expecting double-digit growth [11] Emerging Growth Drivers - **Peripheral Nerve Stimulation (PNS)**: - Current market size of $200 million in the U.S., expected to exceed $500 million by 2029 [12] - Introduction of StimTrial and Talisman PNS system to enhance treatment options [13] - **Platelet-Rich Plasma (PRP)**: - Current market size of $400 million in the U.S., growing in high single digits, with exclusive distribution agreement for Excel PRP system [14] Strategic Focus - **Value Creation**: - Combination of above-market growth and peer-leading gross margin allows for margin expansion while investing in future growth drivers [16][20] - **Cash Flow and Debt Management**: - Expected leverage to drop below 2.5x, providing optionality for capital deployment [18][19] Conclusion - **Future Outlook**: - Bioventus aims to become a $1 billion high-growth, high-profit, high-cash flow company focused on patient recovery and quality of life [20]

Financial Performance & Growth - The company reported Last Twelve Months (LTM) global proforma revenue of $564 million[7] - The company is experiencing above-market revenue growth, with eight quarters of mid-single-digit or higher growth[8] - The company's organic growth is projected at 7% in 2025[12] - The company's Adjusted EBITDA margin is expected to increase from 13.4% in 2022 to 20.2% in 2025[14] - Cash from Operations is projected to nearly double from 2024 to 2025[19] Market & Strategy - The company operates in a $6.4 billion addressable market[7] - The company has a diversified portfolio in large and growing markets, including Pain Treatments, Surgical Solutions, and Restorative Therapies[8, 6] - The company is focused on margin expansion by leveraging mid-70s gross margin and cost efficiencies[8, 24] - The company aims to increase EBITDA and cash flow to continue reducing leverage[8] Future Outlook - The company projects a net leverage ratio of less than 2.5x by the end of 2025[27] - The company anticipates a free cash flow yield of approximately 60% in 2025[27]